CN114806929A - 一株高产罗伊氏菌素的罗伊氏乳杆菌lr4009及其应用 - Google Patents
一株高产罗伊氏菌素的罗伊氏乳杆菌lr4009及其应用 Download PDFInfo
- Publication number
- CN114806929A CN114806929A CN202210322275.1A CN202210322275A CN114806929A CN 114806929 A CN114806929 A CN 114806929A CN 202210322275 A CN202210322275 A CN 202210322275A CN 114806929 A CN114806929 A CN 114806929A
- Authority
- CN
- China
- Prior art keywords
- freeze
- lactobacillus reuteri
- strain
- reuterin
- bacterial sludge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 62
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 62
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 239000000843 powder Substances 0.000 claims abstract description 34
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- 238000004321 preservation Methods 0.000 claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 claims abstract description 11
- 230000036039 immunity Effects 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 63
- 238000000855 fermentation Methods 0.000 claims description 44
- 230000004151 fermentation Effects 0.000 claims description 44
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 239000010802 sludge Substances 0.000 claims description 27
- 239000001963 growth medium Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 18
- OAJLVMGLJZXSGX-SLAFOUTOSA-L (2s,3s,4r,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7 Chemical compound [Co+3].O[C@H]1[C@@H](O)[C@@H]([CH2-])O[C@@H]1N1C2=NC=NC(N)=C2N=C1.[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-SLAFOUTOSA-L 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000008176 lyophilized powder Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009630 liquid culture Methods 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 108010062877 Bacteriocins Proteins 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- 238000011218 seed culture Methods 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 241000894006 Bacteria Species 0.000 abstract description 9
- 239000003833 bile salt Substances 0.000 abstract description 9
- 239000002253 acid Substances 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 210000004051 gastric juice Anatomy 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 11
- 108010025885 Glycerol dehydratase Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- RZOJJJRDQJSMFK-UHFFFAOYSA-N 3,3,3-trihydroxypropanal Chemical compound OC(O)(O)CC=O RZOJJJRDQJSMFK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- BTKIAQUFTPDMOW-UHFFFAOYSA-N roxburghin Natural products Oc1cccc(C=Cc2cc(O)c(O)cc2O)c1 BTKIAQUFTPDMOW-UHFFFAOYSA-N 0.000 description 1
- SHKMVIVFLHPOSB-UHFFFAOYSA-N roxburghine Chemical compound C1=CC=C2C(CCN3CC4C5(C)C6=C(C7=CC=CC=C7N6)CCN5C=C(C4CC33)C(=O)OC)=C3NC2=C1 SHKMVIVFLHPOSB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210322275.1A CN114806929B (zh) | 2022-03-29 | 2022-03-29 | 一株高产罗伊氏菌素的罗伊氏乳杆菌lr4009及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210322275.1A CN114806929B (zh) | 2022-03-29 | 2022-03-29 | 一株高产罗伊氏菌素的罗伊氏乳杆菌lr4009及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114806929A true CN114806929A (zh) | 2022-07-29 |
CN114806929B CN114806929B (zh) | 2023-10-31 |
Family
ID=82533395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210322275.1A Active CN114806929B (zh) | 2022-03-29 | 2022-03-29 | 一株高产罗伊氏菌素的罗伊氏乳杆菌lr4009及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114806929B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115466697A (zh) * | 2022-09-22 | 2022-12-13 | 南昌大学 | 一株罗伊氏乳杆菌hlre05及其应用 |
CN115777856A (zh) * | 2023-01-05 | 2023-03-14 | 苏州硒谷科技有限公司 | 一种富硒高钙红树莓益生菌果肉饮料及其制备方法 |
CN116103198A (zh) * | 2022-12-29 | 2023-05-12 | 河北科星药业有限公司 | 鸡源罗伊氏乳杆菌mc1、筛选方法及其应用 |
CN117402768A (zh) * | 2023-03-13 | 2024-01-16 | 广东悦创生物科技有限公司 | 一株罗伊氏粘液乳杆菌ka1及其在制备抗炎抗肿瘤食品药品中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988008452A1 (en) * | 1987-05-01 | 1988-11-03 | Probiologics International, Inc. | Antibiotic reuterin |
CN107828703A (zh) * | 2017-12-15 | 2018-03-23 | 富乐顿生物工程科技(北京)有限公司 | 空间罗伊氏乳杆菌Fullarton‑9‑35及应用 |
WO2018083336A1 (en) * | 2016-11-07 | 2018-05-11 | Biogaia Ab | Activated lactobacillus reuteri strains for selective pathogen inhibition in a human microbial community |
CN109182397A (zh) * | 2018-09-18 | 2019-01-11 | 北京大伟嘉生物技术股份有限公司 | 一种提高罗伊氏菌素产量的方法 |
WO2019112217A1 (ko) * | 2017-12-05 | 2019-06-13 | 한국생명공학연구원 | 글리세롤로부터 루테린을 고생산하는 락토바실러스 루테리 oh0335 균주 및 이의 용도 |
CN112375715A (zh) * | 2020-11-27 | 2021-02-19 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种改善黄颡鱼高糖饲料利用的罗伊氏乳杆菌菌剂及其制备方法 |
CN112493377A (zh) * | 2020-11-27 | 2021-03-16 | 广东省微生物研究所(广东省微生物分析检测中心) | 含罗伊氏菌素的罗伊氏乳杆菌菌剂在制备促进黄颡鱼糖脂代谢的制剂中的应用 |
-
2022
- 2022-03-29 CN CN202210322275.1A patent/CN114806929B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988008452A1 (en) * | 1987-05-01 | 1988-11-03 | Probiologics International, Inc. | Antibiotic reuterin |
WO2018083336A1 (en) * | 2016-11-07 | 2018-05-11 | Biogaia Ab | Activated lactobacillus reuteri strains for selective pathogen inhibition in a human microbial community |
WO2019112217A1 (ko) * | 2017-12-05 | 2019-06-13 | 한국생명공학연구원 | 글리세롤로부터 루테린을 고생산하는 락토바실러스 루테리 oh0335 균주 및 이의 용도 |
CN107828703A (zh) * | 2017-12-15 | 2018-03-23 | 富乐顿生物工程科技(北京)有限公司 | 空间罗伊氏乳杆菌Fullarton‑9‑35及应用 |
CN109182397A (zh) * | 2018-09-18 | 2019-01-11 | 北京大伟嘉生物技术股份有限公司 | 一种提高罗伊氏菌素产量的方法 |
CN112375715A (zh) * | 2020-11-27 | 2021-02-19 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种改善黄颡鱼高糖饲料利用的罗伊氏乳杆菌菌剂及其制备方法 |
CN112493377A (zh) * | 2020-11-27 | 2021-03-16 | 广东省微生物研究所(广东省微生物分析检测中心) | 含罗伊氏菌素的罗伊氏乳杆菌菌剂在制备促进黄颡鱼糖脂代谢的制剂中的应用 |
Non-Patent Citations (3)
Title |
---|
FEIXIA LIU 等: "Efficient production of reuterin from glycerol by magnetically immobilized Lactobacillus reuteri", APPL MICROBIOL BIOTECHNOL, pages 4659 - 4666 * |
MU Q 等: "Role of Lactobacillus reuteri in Human Health and Diseases", FRONT. MICROBIOL., pages 1 - 17 * |
万心怡 等: "罗伊氏乳杆菌产罗伊氏细菌素的工艺优化.", 食品与生物技术学报, pages 63 - 69 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115466697A (zh) * | 2022-09-22 | 2022-12-13 | 南昌大学 | 一株罗伊氏乳杆菌hlre05及其应用 |
CN115466697B (zh) * | 2022-09-22 | 2023-10-03 | 南昌大学 | 一株罗伊氏乳杆菌hlre05及其应用 |
CN116103198A (zh) * | 2022-12-29 | 2023-05-12 | 河北科星药业有限公司 | 鸡源罗伊氏乳杆菌mc1、筛选方法及其应用 |
CN116103198B (zh) * | 2022-12-29 | 2024-05-24 | 河北科星药业有限公司 | 鸡源罗伊氏乳杆菌mc1、筛选方法及其应用 |
CN115777856A (zh) * | 2023-01-05 | 2023-03-14 | 苏州硒谷科技有限公司 | 一种富硒高钙红树莓益生菌果肉饮料及其制备方法 |
CN117402768A (zh) * | 2023-03-13 | 2024-01-16 | 广东悦创生物科技有限公司 | 一株罗伊氏粘液乳杆菌ka1及其在制备抗炎抗肿瘤食品药品中的应用 |
CN117402768B (zh) * | 2023-03-13 | 2024-03-22 | 广东悦创生物科技有限公司 | 一株罗伊氏粘液乳杆菌ka1及其在制备抗炎抗肿瘤药品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114806929B (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114806929B (zh) | 一株高产罗伊氏菌素的罗伊氏乳杆菌lr4009及其应用 | |
CN116024130B (zh) | 一株降血尿酸发酵乳杆菌a21215及其应用 | |
CN103421715B (zh) | 一种鼠李糖乳杆菌及其应用 | |
CN109749957B (zh) | 一种具有水产病原菌拮抗特性的格氏乳杆菌制剂的制备及应用 | |
CN108348559A (zh) | 用于生产共轭亚油酸的副干酪乳杆菌、含有其的营养制剂和药物制剂及其用途 | |
CN111534459B (zh) | 一株高产淀粉酶的发酵乳杆菌及其在制备发酵饲料中的应用 | |
CN101831481A (zh) | 一种新的伊枯草菌素a及其同系物的制备方法 | |
CN114634885B (zh) | 一株高产γ-氨基丁酸的植物乳杆菌及其应用 | |
CN113773978B (zh) | 青春双歧杆菌及其应用 | |
CN115074290B (zh) | 一种联产苯乳酸和γ-氨基丁酸的干酪乳杆菌及其应用 | |
CN113549574A (zh) | 一种凝结芽孢杆菌及其应用 | |
CN116004436A (zh) | 鼠李糖乳杆菌gs014及其在改善和调节肠道菌群中的应用 | |
CN106497842B (zh) | 一种乳酸菌与黑曲霉混合固态发酵制剂的制备方法与应用 | |
CN116836830A (zh) | 产细菌素的植物乳植杆菌及其应用 | |
KR101951893B1 (ko) | 전통발효식품 유래의 프로바이오틱스활성 락토바실러스 파라카제이 srcm102343 균주의 고농도 제조 방법 | |
CN111676170B (zh) | 一株发酵乳杆菌及其在制备共轭脂肪酸中的应用 | |
CN107779422B (zh) | 一株高效抑制黄曲霉合成黄曲霉毒素的非脱羧勒克菌生防菌株 | |
KR20150054056A (ko) | 갈조류 부산물을 유효성분으로 포함하는 발효사료 | |
CN110878273B (zh) | 一株短双歧杆菌及其在制备共轭脂肪酸中的应用 | |
CN108707569B (zh) | 屎肠球菌高效发酵培养基及其发酵培养方法 | |
CN115895974A (zh) | 一株富硒且高产γ-氨基丁酸的植物乳杆菌及其应用 | |
CN115595332A (zh) | 一种复合酶联合微生物发酵制备银耳发酵液的方法 | |
CN111925972B (zh) | 一种希氏乳杆菌及其应用 | |
CN108504589A (zh) | 一种复合乳酸菌微生态制剂及其制备方法和应用 | |
CN110241052B (zh) | 一株高产叶酸植物乳杆菌gslp-7及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240820 Address after: 271099 No. 17 Huayuan Road, Taishan District, Tai'an City, Shandong Province Patentee after: Shandong Fenghuang Biotechnology Co.,Ltd. Country or region after: China Patentee after: TAIAN DAFANSHENNONG PHARMACEUTICAL Co.,Ltd. Address before: 271099 No. 17 Huayuan Road, Taishan District, Tai'an City, Shandong Province Patentee before: Shandong Fenghuang Biotechnology Co.,Ltd. Country or region before: China |